Abstract
In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1581-1582 |
| Number of pages | 2 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 46 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2002 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint Dive into the research topics of 'In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes'. Together they form a unique fingerprint.
Cite this
Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., & Graybill, J. R. (2002). In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrobial agents and chemotherapy, 46(5), 1581-1582. https://doi.org/10.1128/AAC.46.5.1581-1582.2002